Objective: To study the genetic variation and haplotype structure of Vitamin K epoxide
reductase complex, subunit 1 (VKORC1) gene in the Tamilian population. Materials And …

The article presents a study that investigates the role of genetic polymorphism within the
vitamin K epoxide reductase gene in the response to oral anticoagulants. Results show that …

BACKGROUND: Genetic variation in the vitamin K epoxide reductase complex (VKORC1)
and cytochrome P450 4F2 (CYP4F2) genes were found to be strongly associated with the …

A daily dose of vitamin K antagonists (VKAs) may vary and its range depends on various
interrelated factors. Low responsiveness to VKA (defined as a failure to achieve a target …

Dear Sir, Oral anticoagulant (OA) drugs are a mainstay for the prevention andtreatmentofthromboembolicdiseasebute…
tofrequenthaemorrhagicsideeffects (1). ThisOAhaemorrhagic risk depends on …

Warfarin is the most commonly prescribed anticoagulant drug for both prophylaxis and
treatment of thromboembolic disorders. The main alternatives to warfarin are …

Sažetak Vitamin K epoxide reductase (VKOR) is a key enzyme in the g-carboxylation of
proteins associated with important bodily functions (coagulation, bone metabolism, etc.) …

BACKGROUND: The dose requirements for oral anticoagulants in thromboembolic events
are influenced by promoter polymorphism in the VKORC1 gene. However, limited data are …

Polymorphisms in vitamin K epoxide reductase complex subunit 1 (VKORC1) gene lead to
interindividual variability in warfarin dose requirement. The characterization of genotype …

Warfarin dose requirements have been associated with 2 main haplotypes in VKORC1, but
the responsible polymorphisms remain unknown. To search for regulatory polymorphisms …